cyp51 Antibody

What is CYP51 and why are antibodies against it important in research?

CYP51 (cytochrome P450 family 51 subfamily A member 1) represents one of the most ancient and conserved P450 protein families, with members distributed across virtually all biological kingdoms. It functions as a Sterol 14alpha-demethylase playing a critical role in the cholesterol biosynthesis pathway, with cholesterol being the major sterol component in mammalian membranes and a precursor for bile acid and steroid hormone synthesis . CYP51 antibodies provide researchers with the ability to specifically detect and study this protein in various experimental settings, facilitating investigations into its expression patterns, subcellular localization, functional interactions, and involvement in disease mechanisms.

What applications are CYP51 antibodies commonly used for in research laboratories?

The search results reveal CYP51 antibodies are utilized in multiple research applications including:

• Western blotting (WB) for protein expression quantification

• Enzyme-linked immunosorbent assay (ELISA) for sensitive detection

• Flow cytometry (FCM) for cell-based analyses

• Immunocytochemistry (ICC) and immunofluorescence (IF) for cellular localization studies

• Immunohistochemistry (IHC) for tissue expression analysis

• Immunoprecipitation (IP) for protein-protein interaction studies

These diverse applications enable comprehensive characterization of CYP51 across multiple experimental paradigms, from molecular-level interactions to tissue-wide distribution patterns.

What species reactivity is available for CYP51 antibodies?

Commercial CYP51 antibodies demonstrate reactivity across multiple species, reflecting the highly conserved nature of this protein throughout evolution. According to the search results, available antibodies show reactivity to:

• Human (Hu)

• Mouse (Ms)

• Rat (Rt)

• Monkey (Mk)

• Pig (Pg)

• Zebrafish (Zf)

• Mycobacterium species

This multi-species reactivity enables comparative studies across various model organisms, supporting evolutionary and translational research approaches.

How does epitope selection influence CYP51 antibody performance across different experimental applications?

The choice of target epitope significantly impacts CYP51 antibody performance across experimental platforms. For membrane-associated proteins like CYP51 that localize to the endoplasmic reticulum, epitope accessibility varies considerably depending on the technique:

When selecting CYP51 antibodies, researchers should evaluate whether the epitope is preserved in their experimental conditions, particularly with fixation-dependent applications like immunohistochemistry where epitope masking can occur. Cross-validation with multiple antibodies targeting different regions of CYP51 is recommended for confirming results, especially in novel experimental systems.

How can CYP51 antibodies be utilized in research on neglected tropical diseases?

CYP51 represents a validated drug target in neglected tropical diseases (NTDs), particularly those caused by kinetoplastid parasites like Trypanosoma cruzi (Chagas disease) and some Leishmania species . Researchers can implement CYP51 antibodies in NTD research through several sophisticated approaches:

• Target validation studies: Confirm the expression, localization, and essentiality of CYP51 in parasite lifecycle stages through immunodetection techniques.

• Drug mechanism studies: Investigate how potential therapeutics affect CYP51 expression, localization, or post-translational modifications using Western blotting and immunocytochemistry.

• Resistance monitoring: Detect alterations in CYP51 expression or variants in field isolates or laboratory-induced resistant strains through comparative antibody-based analyses.

• Structure-function relationship studies: Combined with x-ray crystallography data from parasite CYP51 structures , antibodies can validate computational predictions about protein domains critical for function or drug binding.

• High-throughput screening support: In phenotypic screens for new antiparasitic compounds, CYP51 antibodies help identify whether hit compounds affect the CYP51 pathway through target engagement studies.

The specificity of these investigations is crucial since parasites like T. cruzi require endogenous sterol biosynthesis, whereas T. brucei bloodstream forms depend on host cholesterol while their insect forms rely on endogenous sterol synthesis .

What approaches should be used to investigate the relationship between CYP51 inhibition and sterol pathway disruption?

Investigating the relationship between CYP51 inhibition and sterol biosynthesis disruption requires integrative approaches combining antibody-based techniques with metabolite analysis. Since CYP51 inhibition not only blocks ergosterol production but also leads to accumulation of methylated toxic intermediates , comprehensive experimental designs should include:

• Parallel analysis of CYP51 protein levels (using validated antibodies) and sterol metabolite profiles (using gas chromatography-mass spectrometry).

• Time-course experiments correlating CYP51 inhibition kinetics with the accumulation of 14α-methylated sterol intermediates and depletion of end-product sterols.

• Comparative studies between pharmacological inhibition (using established CYP51 inhibitors) and genetic manipulation (using RNAi or CRISPR-based approaches).

• Co-localization studies using CYP51 antibodies and fluorescent sterol probes to track subcellular distribution changes following treatment.

The accumulated knowledge from x-ray crystallography studies of CYP51 from multiple species, including Mycobacterium tuberculosis, Trypanosoma cruzi, Trypanosoma brucei, Leishmania infantum, Saccharomyces cerevisiae, and humans provides structural templates to understand the molecular basis of inhibition mechanisms.

What are the optimal protocols for Western blot analysis using CYP51 antibodies?

For robust Western blot analysis of CYP51, researchers should implement the following optimized protocol:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors for effective extraction of ER-localized CYP51

  • Include reducing agents (β-mercaptoethanol or DTT) to ensure proper denaturation

  • Heat samples at 95°C for 5 minutes to fully denature the protein

• Gel electrophoresis:

  • Use 10-12% polyacrylamide gels for optimal resolution of the 509-amino acid CYP51 protein

  • Load appropriate positive controls (liver tissue lysate is recommended due to high expression levels)

• Transfer conditions:

  • For the ~55-60 kDa CYP51 protein, semi-dry transfer at 15V for 30 minutes or wet transfer at 100V for 1 hour

  • Use PVDF membrane for better protein retention and stronger signal

• Antibody incubation:

  • Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • Dilute primary antibody according to manufacturer's recommendation (typically 1:500-1:2000)

  • Incubate overnight at 4°C for optimal binding

  • Use appropriate HRP-conjugated secondary antibodies at 1:5000-1:10000 dilution

• Controls and validation:

  • Include positive control (liver tissue extract)

  • Include negative control (tissue known to express low levels of CYP51)

  • Consider using CYP51 knockdown or knockout samples as specificity controls

The expected molecular weight for human CYP51 is approximately 57 kDa, and researchers should optimize conditions for their specific antibody as recommendations may vary between manufacturers .

How should researchers approach immunohistochemistry experiments to study CYP51 expression across different tissues?

When designing immunohistochemistry (IHC) experiments to study CYP51 tissue distribution, researchers should implement this systematic approach:

• Tissue processing optimization:

  • Use 10% neutral buffered formalin fixation (8-24 hours depending on tissue size)

  • For sensitive epitopes, consider shorter fixation times or alternative fixatives

  • Implement standardized processing protocols across all experimental samples

• Antigen retrieval method selection:

  • Begin with heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • For challenging samples, test alternative methods like Tris-EDTA (pH 9.0)

  • Optimize retrieval conditions for each tissue type being examined

• Blocking and antibody parameters:

  • Block endogenous peroxidase with 3% hydrogen peroxide

  • Use serum-free protein block to reduce non-specific binding

  • Dilute antibody according to validation studies (typically 1:100-1:500)

  • Incubate at 4°C overnight for optimal sensitivity and specificity

• Detection system considerations:

  • Employ polymer-based detection systems for superior sensitivity

  • For multiplex staining, use spectral unmixing or sequential detection protocols

  • Include appropriate chromogens for desired visualization and archiving

• Validation approach:

  • Use liver tissue as positive control (CYP51 is highly expressed)

  • Include appropriate negative controls (primary antibody omission, isotype controls)

  • Confirm findings with orthogonal methods (Western blot, qPCR)

  • Consider using tissue microarrays for standardized comparative analysis

• Quantification strategy:

  • Implement digital image analysis with consistent parameters

  • Use H-score or other standardized scoring systems

  • Analyze multiple fields per sample (minimum 5-10 high-power fields)

  • Conduct blind scoring by multiple observers for objective assessment

Following this methodological framework will ensure reproducible and meaningful data on CYP51 tissue distribution patterns.

What considerations are important when using CYP51 antibodies for comparative studies across different species?

For rigorous cross-species CYP51 studies using antibodies, researchers must address several critical methodological considerations:

• Epitope conservation analysis:

  • Perform sequence alignments of CYP51 across target species

  • Select antibodies targeting highly conserved epitopes for cross-species detection

  • For species-specific studies, choose antibodies targeting divergent regions

  • Consider the evolutionary distance between species when interpreting results

• Validation requirements for each species:

  • Verify appropriate molecular weight by Western blot in each species

  • Confirm subcellular localization patterns through immunofluorescence

  • Use positive and negative tissue controls from each species

  • Include recombinant protein standards when available

• Protocol optimization for each species:

  • Adjust fixation times based on tissue characteristics

  • Modify antigen retrieval conditions for each species' tissues

  • Titrate antibody concentrations separately for each species

  • Optimize blocking reagents to minimize species-specific background

• Data interpretation frameworks:

  • Consider differences in post-translational modifications between species

  • Account for species variation in CYP51 expression levels

  • Normalize to appropriate housekeeping proteins for each species

  • Implement parallel methodologies for cross-validation

The structural conservation of CYP51 across evolutionary distances makes it particularly suitable for comparative studies, but careful attention to these methodological details is essential for generating reliable data .

How should researchers interpret contradictory results between CYP51 antibody detection and mRNA expression data?

When confronted with discrepancies between CYP51 protein levels (detected via antibodies) and mRNA expression, researchers should implement a systematic analytical framework:

• Biological mechanism assessment:

  • Evaluate post-transcriptional regulation through miRNA analysis

  • Investigate protein stability differences using pulse-chase experiments

  • Examine post-translational modifications that might affect antibody recognition

  • Consider alternative splicing variants that could impact detection

• Technical validation approach:

  • Verify antibody specificity using knockout/knockdown controls

  • Test multiple antibodies targeting different CYP51 epitopes

  • Confirm mRNA measurements with alternative methods (RNA-seq, qPCR)

  • Assess detection sensitivity limits for both protein and mRNA methods

• Time-course analysis:

  • Implement time-resolved experiments to detect temporal shifts between transcription and translation

  • Monitor protein and mRNA stability under experimental conditions

  • Consider circadian or other cyclical regulation patterns

  • Examine the kinetics of response to experimental perturbations

• Context-dependent interpretation:

  • Evaluate tissue-specific regulatory mechanisms

  • Consider cell-type heterogeneity within complex samples

  • Assess stress responses that might differentially affect mRNA and protein levels

  • Examine the influence of experimental conditions on both transcription and translation

These discrepancies often reveal important biological regulatory mechanisms rather than experimental errors, potentially leading to novel insights into CYP51 regulation in different physiological and pathological contexts.

What approaches can integrate CYP51 structural data with antibody-based experimental results?

Integrating structural insights from CYP51 X-ray crystallography with antibody-based experimental results creates powerful research synergies through these methodological approaches:

• Epitope mapping on structural models:

  • Map antibody epitopes onto 3D structures from X-ray crystallography data

  • Assess epitope accessibility in different protein conformations

  • Predict how mutations might affect antibody binding

  • Visualize epitopes relative to functional domains and active sites

• Structure-guided experimental design:

  • Select antibodies targeting specific functional regions based on structural insights

  • Design site-directed mutagenesis experiments for structure-function analysis

  • Create domain-specific antibodies for mechanistic studies

  • Develop conformation-specific antibodies to detect structural changes

• Computational prediction validation:

  • Use antibodies to validate in silico predictions about protein-protein interactions

  • Confirm structural changes predicted by molecular dynamics simulations

  • Verify accessibility of domains in different experimental conditions

  • Test structural models through epitope accessibility studies

This integrated approach combining structural biology with antibody-based detection provides comprehensive insights into CYP51 structure-function relationships and supports rational drug design efforts targeting this enzyme in various disease contexts .

What statistical approaches are most appropriate for analyzing CYP51 expression across experimental conditions?

For robust statistical analysis of CYP51 expression data, researchers should implement these methodological recommendations:

• Experimental design considerations:

  • Conduct power analysis to determine adequate sample size

  • Include minimum 3-5 biological replicates per condition

  • Implement technical replicates to account for assay variability

  • Design appropriate controls for normalization and comparison

• Normalization strategies:

  • For Western blot: Normalize to housekeeping proteins (β-actin, GAPDH) or total protein

  • For qPCR: Use geometric mean of multiple reference genes

  • For IHC: Apply positive pixel count or H-score normalization

  • For flow cytometry: Utilize isotype controls and fluorescence minus one controls

• Statistical test selection:

  • Two-group comparison: Student's t-test (parametric) or Mann-Whitney U test (non-parametric)

  • Multiple group comparison: One-way ANOVA with post-hoc tests (Tukey, Bonferroni)

  • Repeated measures: Repeated measures ANOVA or mixed models

  • Non-normal data: Apply logarithmic transformation or non-parametric tests

• Advanced analytical approaches:

  • Correlation analysis: Pearson's or Spearman's for association with phenotypic parameters

  • Regression analysis: For identifying predictors of CYP51 expression

  • Multivariate analysis: Principal component analysis for complex datasets

  • Meta-analysis: For integrating results across multiple studies

• Reporting standards:

  • Present mean ± standard deviation or median with interquartile range

  • Use box plots or violin plots to show distribution

  • Include individual data points for transparency

  • Report exact p-values and confidence intervals

These approaches ensure robust and reproducible analysis of CYP51 expression data across experimental conditions, enhancing the reliability and impact of research findings.

How can researchers distinguish between host and pathogen CYP51 in infection models?

Distinguishing between host and pathogen CYP51 in infection models is methodologically challenging but crucial for therapeutic development. Researchers should implement these specialized approaches:

• Antibody-based differentiation strategies:

  • Develop species-specific antibodies targeting divergent regions between host and pathogen CYP51

  • Use sequence alignment to identify unique epitopes for selective antibody generation

  • Validate antibody specificity using recombinant proteins from both species

  • Implement peptide competition assays to confirm epitope specificity

• Experimental design considerations:

  • Include uninfected controls to establish baseline host CYP51 expression

  • Use purified pathogen cultures as positive controls for pathogen-specific detection

  • Create mixed samples with known ratios to establish detection limits

  • Implement time-course experiments to track expression changes during infection progression

• Advanced visualization techniques:

  • Apply dual immunofluorescence labeling with species-specific antibodies

  • Utilize confocal microscopy with Z-stack analysis for spatial resolution

  • Implement super-resolution microscopy for detailed co-localization studies

  • Employ spectral unmixing for distinguishing closely related fluorophores

• Molecular differentiation approaches:

  • Develop species-specific PCR assays for gene expression analysis

  • Use mass spectrometry with selected reaction monitoring for peptide-level distinction

  • Implement CRISPR/Cas9 to tag endogenous CYP51 in host or pathogen

  • Create reporter systems with species-specific promoters

These methodological approaches enable precise discrimination between host and pathogen CYP51, facilitating targeted therapeutic development with reduced off-target effects on host sterol biosynthesis .

What approaches can determine whether CYP51 inhibitors are selective for pathogen over host enzymes?

Evaluating selectivity of CYP51 inhibitors between pathogen and host enzymes requires multifaceted methodological approaches:

• Biochemical selectivity assessment:

  • Conduct parallel enzyme inhibition assays with purified host and pathogen CYP51

  • Determine IC50 values and calculate selectivity indices

  • Perform kinetic analyses to distinguish competitive vs. non-competitive inhibition

  • Measure binding affinity through thermal shift assays or isothermal titration calorimetry

• Structural basis for selectivity:

  • Utilize X-ray crystallography data from pathogen and host CYP51

  • Perform comparative molecular docking studies

  • Identify species-specific binding pocket differences

  • Design compounds exploiting structural differences between species

• Cellular selectivity validation:

  • Compare growth inhibition in pathogen versus host cells

  • Measure CYP51 activity in intact cells using substrate conversion assays

  • Analyze sterol profiles to confirm targeted pathway disruption

  • Evaluate cytotoxicity profiles across concentration ranges

• In vivo confirmation approaches:

  • Assess therapeutic index in animal infection models

  • Monitor pathogen clearance versus host side effects

  • Analyze tissue-specific effects on sterol biosynthesis

  • Evaluate pharmacokinetic/pharmacodynamic relationships

• Resistance development monitoring:

  • Select for resistant mutants and sequence CYP51

  • Identify cross-resistance patterns between compounds

  • Determine structural basis of resistance

  • Assess fitness costs of resistance mutations

This comprehensive approach ensures development of CYP51 inhibitors with optimal selectivity profiles, a critical requirement for successful therapeutic applications in infectious diseases while minimizing host toxicity.

How should researchers design experiments to evaluate CYP51 inhibitors in combination with other antiparasitic agents?

Designing robust experiments to evaluate CYP51 inhibitors in combination with other antiparasitic agents requires sophisticated methodological approaches:

• Interaction assessment strategies:

  • Implement checkerboard assays for comprehensive dose-response matrices

  • Calculate combination indices using Chou-Talalay method

  • Apply isobologram analysis to visualize synergistic, additive, or antagonistic effects

  • Use response surface modeling for complex interactions

• Mechanism-based combination design:

  • Target multiple steps in sterol biosynthesis pathway

  • Combine membrane-disrupting agents with CYP51 inhibitors

  • Pair CYP51 inhibitors with efflux pump inhibitors to enhance accumulation

  • Evaluate combinations with immune modulators for host-directed therapy

• Temporal dynamics evaluation:

  • Test different administration sequences (simultaneous vs. staggered)

  • Implement time-kill curve analysis for combination effects

  • Assess post-antibiotic effect duration in combination treatments

  • Monitor parasite recovery rates following exposure

• Resistance prevention assessment:

  • Determine mutation prevention concentration for combinations

  • Measure resistance development rates compared to monotherapy

  • Characterize any emerging resistant variants

  • Evaluate cross-resistance profiles to other drug classes

• In vivo combination validation:

  • Assess pharmacokinetic interactions between compounds

  • Determine optimal dosing schedules in animal models

  • Evaluate efficacy/toxicity profiles of combinations

  • Monitor biomarkers of target engagement for multiple agents

These methodological approaches provide comprehensive evaluation of CYP51 inhibitor combinations, potentially addressing limitations of monotherapy including efficacy gaps and resistance development while enabling reduced dosing of individual agents to minimize toxicity .